Geron Corporation announced that its management team will present at the Bank of America Securities 2026 Healthcare Conference on May 12 and the Stifel Virtual Targeted Oncology Forum on May 20. These presentations will provide updates on Geron's commercial-stage biopharmaceutical developments, including its approved telomerase inhibitor RYTELO® for certain blood cancers and ongoing Phase 3 trials. Investors can access live and archived webcasts on Geron's website. This engagement highlights Geron's efforts to advance treatments for blood cancer and keep investors informed on progress and clinical developments.
Smart Clerk, an AI-powered bookkeeping platform, has surpassed 6,000 small business users who rely on its tools to simplify bookkeeping and generate tax-ready reports. The platform recently enhanced its connectivity by integrating with financial data...
The sulfuric acid market is projected to grow from $41.23 billion in 2025 to $49.94 billion by 2030 at a CAGR of 3.9%. Growth is driven by rising demand in metal processing, especially for base metals used in construction, electronics, and renewable ...
SpaceX shares have surged above $170 shortly after its IPO, surpassing two of three early analyst price targets. Initial targets ranged from $165 to $190, with the stock closing near $161 on the first day and rising to around $170 by the second day. ...
Tesla has been accused of presenting misleading safety data to European regulators to gain approval for its Full Self-Driving (FSD) system. Independent researchers and Reuters found that Tesla exaggerated its safety claims by using unrealistic assump...
On World Elder Abuse Awareness Day, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) raised awareness about elder financial abuse, which involves billions in suspected losses annually. They shared practical tips to p...
